Hemlibra Patent Dispute Spills Over Into Patient Community
Executive Summary
After Shire seeks preliminary injunction to carve-out certain patients from obtaining the hemophilia treatment, Genentech issues open letter saying patients should not be put in the middle of a patent dispute.
You may also be interested in...
Hemophilia Community Not 'Choosing A Side' In Hemlibra Litigation
Shire explains why it is seeking preliminary injunction against Genentech; National Hemophilia Foundation and Hemophilia Federation of America decline to take position on dispute.
Genentech's Hemlibra: Clinical Outcome Assessment Data Only Partially Swayed US FDA
Hemophilia A drug's labeling reflects data on physical function improvement because FDA deemed that portion of the Haem-A-QoL instrument fit for purpose, while other questions were viewed as insensitive to change or irrelevant. Review documents suggest agency was unimpressed with results from a health status instrument frequently used in economic analyses.
US FDA Sought Patient Viewpoint On Hemlibra's Benefit/Risk Profile
Hemophilia patient advocate expressed concerns to FDA about ability of hemophilia treatment centers to educate patients about thrombotic microangiopathy and thromboembolic events, unexpected but serious cases of which were seen in the clinical program.